Michael Joseph Golembiewski - 29 Feb 2024 Form 4 Insider Report for SEELOS THERAPEUTICS, INC.

Role
Chief Financial Officer
Signature
/s/ Michael Golembiewski
Issuer symbol
N/A
Transactions as of
29 Feb 2024
Net transactions value
+$457
Form type
4
Filing time
01 Mar 2024, 17:39:18 UTC
Previous filing
17 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SEEL Common Stock Award $457 +417 +0.48% $1.10 86,869 29 Feb 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired under the Company's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2 Effective on November 28, 2023, the Issuer conducted a reverse stock split at a ratio of 1-for-30 (the "Reverse Split"). The number of shares reported herein reflects the number of shares after the Reverse Split.